Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies

Italian Heart Journal

Volumn 1, Issue 9, 2000, Pages 595-604

  Di Pasquale, P ^a   Di Stefano, G ^a   Paterna, S ^a  

^a Ospedale GF Ingrassia   (Italy)

Author keywords

Aldosterone; Aldosterone receptor antagonists; Heart failure

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; COLLAGEN; CORTICOSTERONE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; GROWTH FACTOR; LOSARTAN; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; RAMIPRIL; SPIRONOLACTONE;

APOPTOSIS; BLOOD PRESSURE; BLOOD VESSEL TONE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; FIBROBLAST; FIBROSIS; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUDDEN DEATH;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL; APOPTOSIS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; CORONARY VESSELS; FIBROSIS; HEART FAILURE, CONGESTIVE; HUMAN; MINERALOCORTICOIDS; MYOCARDIAL INFARCTION; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A;

EID: 0033788074     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
2. GISSI-3: Effects of lisinopril and transdermal glyceryl tfinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
3. A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in over 58 050 patients with suspected acute myocardial infarction: ISIS-4
4. Pathological hypertrophy and cardiac interstitium fibrosis and renin-angiotensin-aldosterone system
5. Aldosterone and antialdosterone therapy in congestive heart failure
6. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension
7. Ventricular remodeling after myocardial infarction: Experimental observation and clinical implications
8. Structural basis for heart failure: Ventricular re modeling and its pharmacological inhibition
9. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats
10. The neurohumoral axis in congestive heart failure
11. Prognostic value of plasma endothelin-1 in patients with heart failure
12. Adrenergic effects on the biology of the adult mammalian cardiocyte
13. Cardiac myocyte necrosis induced by angiotensin II
14. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts
15. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation
16. Cytokine expression increases in nonmyocytes from rats with postin-farction heart failure
17. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin
18. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
19. Apoptosis in heart failure
20. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure
21. Novel mechanism in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol
22. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
23. The effects of tumor necrosis factor-alpha on cardiac structure and function - A tale of two cytokines
24. Cytokine gene expression after myocardial infarction in rats heart; possible implication in left ventricular remodeling
25. Oxidative stress as a mediator of apoptosis
26. Stretch-induced programmed myocyte cell death
27. Hypothesis: Apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload
28. Apoptosis in the failing heart
29. Diastolic geometry and sarcomeric lengths in the chronically dilated left ventricle
30. Ultrastructural basis of acute left ventricular failure from severe acute aortic stenosis in the rabbit
31. Stretching cardiac myocytes stimulates protoncogene expression
32. Modulation of cardiac genes by mechanical stress: The oncogene signaling hypothesis
33. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy
34. Roles of mechano-sensitive ion channels, cytoskeleton, and contractile activity in stretch-induced immediate-early gene expression and hypertrophy of cardiac myocytes
35. Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: Potential involvement of an autocrine/paracrine mechanism
36. Angiotensin II activates programmed cell death in vitro
37. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability
38. Inhibition of early atherogenesis by losartan in monkey with diet-induced hypercholesterolemia
39. Interleukin family of cytokines and gp130
40. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts
41. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor
42. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
43. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis
44. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β
45. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses
46. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
47. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
48. Increased matrix metallo-protease activity and selective upregulation in LV myocardium from patients with end-stage heart failure
49. Differential gene expression of extracellular matrix components in dilated cardiomyopathy
50. Matrix metalloprotease activity expression in infarcted, non infarcted and dilated cardiomyopathic human hearts
51. Differential expression of tissue inhibitors of metalloprotease in the failing human heart
52. Myocardial fibrosis-functional significance and regulatory factors
53. Structural remodeling in hypertensive heart disease and the role of the hormones
54. Biological determinants of aldosterone-induced cardiac fibrosis in rats
55. Mineralocorticoids, hypertension and cardiac fibrosis
56. Adrenal steroids and cardiac fibrosis
57. Determinants of cardiac fibrosis in experimental hypermineralo-corticoid states
58. Vascular and cardiac actions of aldosterone and spironolactone
59. Activation of matrix metalloproteinases in the failing human heart; breaking the tie that binds
60. Glucocorticoids and mineralocorticoids: Antifibrotic and profibrotic components of wound healing
61. Hormones and fibrosis: A case for lost reciprocal regulation
62. Remodeling of rat right and left ventricles in experimental hypertension
63. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism
64. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat
65. Effects of adding spironolactone to an angiotensin converting enzyme inhibitor in chronic congestive heart failure secondary to coronary heart disease
66. Vascular aldosterone biosynthesis and a link to angiotensin II induced hypertrophy of vascular smooth muscle cells
67. Aldosterone biosynthesis in the rat brain
68. Synthesis of corticosterone in the vascular wall
69. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation
70. Production of aldosterone in isolated rat blood vessels
71. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor
72. Inhibition of tissue repair by spironolactone: Role of mineralocorticoids in fibrous tissue formation
73. Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues
74. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart
75. + dependent 11beta-hydroxysteroid dehydrogenase in the human heart
76. Glucocorticoid metabolism in the cardiac interstitium: 11β-Hydroxysteroid dehydrogenase activity in cardiac fibroblasts
77. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone
78. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone and aldosterone antagonist
79. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo
80. Aldosterone regulates collagen output of rat cardiac fibroblasts by up-regulation of endothelin receptors
81. Cardiovascular, renal, and endocrine responses to intravenously endothelin in conscious dogs
82. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril treated hypertensive rats
83. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis
84. Expression of 11β-hydroxysteroid dehydrogenase mRNA in rat vascular smooth muscle cells
85. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells
86. Aldosterone regulation of gene transcription leading to control of ion transport
87. Transcriptional regulation of Na, K, ATPase α-1 gene expression evidence for oncogene and hormone mediated transcriptional factor interactions
88. + ATPase α subunit gene expression in hypertension
89. +-ATPase pumps in rabbit cortical collecting tubules is aldosterone-dependent
90. Extraadrenal mineralocorticoids and cardiovascular tissue
91. Angiotensin convening enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone
92. Angiotensin II and extracellular matrix homeostasis
93. Angiotensin I converting enzyme inhibitors and cardiac remodeling
94. Role of left ventricular dysfunction in the recovery phase of anterior wall acute myocardial infarction
95. Tissue specific activation of cardiac angiotensin converting enzyme in experimental heart failure
96. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat
97. Survival after myocardial infarction in the rat. Role of tissue angiotensin converting enzyme inhibition
98. Contribution of cardiac renin angiotensin system to ventricular remodelling in myocardial-infarcted rats
99. Selective activation of cardiac angiotensinogen expression in postin-farction ventricular remodelling in the rat
100. Angiotensin II receptor binding following myocardial infarction in the rat
101. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction
102. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study
103. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type I receptor blockade on cardiac remodeling after myocardial infarction in the rat
104. Role of tissue renin in the regulation of aldosterone biosynthesis in the adrenal cortex of the nephrectomized rats
105. Activation of cardiac aldosterone production in rat myocardial infarction
106. The combination ACE-inhibitors plus canreonate in patients with anterior myocardial infarction: Safety and tolerability study
107. Failure to treat heart failure
108. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
109. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
110. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure
111. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart
112. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon
113. Pathologic hypertrophy with fibrosis; the structural basis for myocardial failure
114. Myocardial fibrosis and elevations in plasma aldosterone in arterial hypertension
115. ANF and the renin-angiotensin system in the regulation of sodium balance: Longitudinal studies in experimental heart failure
116. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
117. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
118. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
119. Evidence of partial escape of renin angiotensin aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors
120. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
121. Captopril in heart failure a double blind controlled trial
122. Aldosterone and spironolactone in heart failure
123. Readmission after hospitalization for congestive heart failure among medicare beneficiaries
124. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
125. Mechanism of disease: Hormones and hemodynamics in heart failure
126. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure
127. Combined treatment with losartan and enalapril vs enalapril on neurohormonal activation in patients with heart failure
128. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators
129. Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: Randomized and double-blind study
130. Capoten tablets: Captopril tablets
131. Vasotec tablets enalapril maleato
132. Angiotensin independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion
133. Relation of the renin angiotensin aldosterone system to clinical state in congestive heart failure
134. Effects of aldosterone, spironolactone and potassium canrenoate on the isolated perfused working rat heart with and without ischemia
135. Results of endomyocardial biopsy in patients with spontaneous ventricular tachycardia but without apparent structural heart disease
136. Cardiac histologic findings in patients with life-threatening ventricular arrhythmias of unknown origin
137. Evidence for angiotensin-converting enzyme and chymase-mediated angiotensin H formation in the interstitial fluid space of the dog heart in vivo